Rhythm Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary

• Rhythm Pharmaceuticals Inc RYTM.OQ reported a quarterly adjusted loss of 73 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -76 cents. The mean expectation of eleven analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from $-1.23 to -57 cents per share.

• Revenue rose 47.8% to $33.25 million from a year ago; analysts expected $32.52 million.

• Rhythm Pharmaceuticals Inc's reported EPS for the quarter was a loss of 73 cents​.

• The company reported a quarterly loss of $44.97 million.

• Rhythm Pharmaceuticals Inc shares had risen by 1.1% this quarter and gained 15.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $64.00

This summary was machine generated from LSEG data November 6 at 04:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)